FDA Approves Guardant360 CDx for BRAF-Mutant Colorectal Cancer

Guardant Health’s Guardant360 CDx is now FDA-approved to identify BRAF V600E-mutant colorectal cancer patients, helping guide targeted therapy quickly with a simple blood test.